Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6982082

Title:Gene therapy by cell specific targeting
Inventors:Schreiber, Stuart L.; Boston, MA, USA
Belshaw, Peter J.; Somerville, MA, USA
Crabtree, Gerald; Woodside, CA, USA
Summary:Described herein is a novel polypeptide interaction trap assay which employs the use of prokaryotic host cells in producing fusion proteins which activate reporter genes. Central to the invention is a modified cyclosporin A and a modified, genetically engineered version of its receptor, cyclophilin. Methods are disclosed by which host-versus-graft disease following blood marrow transplantation is treated by transfected stem cells which are introduced into a patient such that modified cyclophilin is expressed and modified cyclosporin A is administered to the patient as necessary. The result is a method for inhibiting the proliferation of genetically engineered T cells comprising a nucleic acid encoding a mutated macrolide binding protein (MBP) selected from an FK506-binding protein (FKBP), cyclophilin, calcineurin, and FKBP:rapamycin associated protein (FRAP). Therapeutic applications emphasize intervention in host-versus-graft disease.
Abstract:This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6982082
Application Number:US1997000922240
Date Filed:27/08/1997
Date Published:03/01/2006
Assignee:President and Fellows of Harvard College, Cambridge, MA, USA Board of Trustees of the Leland Stanford Junior University, Stanford, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/15/2020